MedRx Co., Ltd
Tokyo Stock Exchange 4586.T
MedRx Co., Ltd Free Cash Flow Yield on January 14, 2025: -28.40%
-
MedRx Co., Ltd 52-week high Free Cash Flow Yield is -17.91% on August 28, 2024, which is 36.92% above the current Free Cash Flow Yield.
-
MedRx Co., Ltd 52-week low Free Cash Flow Yield is -29.67% on December 26, 2024, which is -4.47% below the current Free Cash Flow Yield.
-
MedRx Co., Ltd average Free Cash Flow Yield for the last 52 weeks is -23.67%.
| Date | Free Cash Flow Yield | Market Value Added (MVA) | Price to Book Ratio (P/B) | Price to Earnings Ratio (P/E) |
|---|
| CEO | Mr. Yonehiro Matsumura |
| IPO Date | Feb. 14, 2013 |
| Location | Japan |
| Headquarters | 431-7 Nishiyama |
| Employees | 22 |
| Sector | Health Care |
| Industries | |
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer's disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email